Introduction to Easd 2017 Poster 870
Let's dive into the details surrounding Easd 2017 Poster 870. Geoffrey Rezvani Glycaemic control, weight loss, and use of other antihyperglycaemics in patients with type 2 diabetes initiated on ...
Easd 2017 Poster 870 Comprehensive Overview
Mahender Yadagiri One year metabolic outcomes in the ABCD nationwide canagliflozin audit ... Alexios Sotiropoulos The effect of ideglira on glycaemic control and cardiometabolic risk factors compared to the non fixed ... https://www.
Gill Hamilton Characteristics of patients with type 2 diabetes initiating canagliflozin compared with other treatment regimens in the ...
Summary & Highlights for Easd 2017 Poster 870
- Juan Frias Impact of lixisenatide (LIXI) dose range on glycaemic outcomes with fixed-ratio combination iGlarLixi in patients with ...
- Ji Cheol Bae Efficacy and safety of fixed-dose combination therapy of gemigliptin/rosuvastatin compared to each mono therapy in ...
- Brett Lauring Safety and efficacy of ertugliflozin in combination with sitagliptin in patients with type 2 diabetes inadequately ...
- Richard Pratley Safety and efficacy of ertugliflozin plus sitagliptin vs either treatment alone after 52 wks in patients with type 2 ...
- https://www.
That wraps up our extensive overview of Easd 2017 Poster 870.